DOR BioPharma, Inc. Announces Positive Interim Results from Phase I Clinical Trial of RiVax(TM), its Ricin Toxin Vaccine
21-Jun-2005
RiVax(TM) is a form of ricin that consists of a fragment of the toxin that has been proven in pre-clinical studies to be non-toxic but retains the capacity to elicit protective immunity.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Pantarhei Bioscience announces discovery of antigen (ZP3) as a treatment to combat ovarian cancer
Go to page
E-T-A Elektrotechnische Apparate GmbH - Altdorf, Germany
Go to page
Honey_bee_pheromones
Go to page
Lipoid AG - Steinhausen, Switzerland
Go to page
How the brain builds panoramic memory - Neuroscientists identify brain regions key to linking different views of our surroundings.
Go to page
European Commission earmarks EUR12 million for plant growth research
Go to page
Lumos Diagnostics - Carlsbad, USA
Go to page
Archemix and SomaLogic Align to Advance the Use of Aptamers - Alliance Promotes Development of Novel Diagnostics and Therapeutics
Go to page
Rovalab - Teltow, Germany
Go to page